Nevro earned FDA approval and began a limited market release of its HFX iQ spinal cord stimulator with HFX AdaptivAI, the company said Sept. 24.
HFX AdaptivAI combines insights from more than 100 million data points and more than 100,000 patients for responsive and personalized pain relief, according to a news release. The spinal cord stimulator provides real-time insights and remote monitoring for physicians.
Nevro plans a full U.S. market release of HFX iQ with HFX AdaptiveAI in the fourth quarter of 2024.